Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

Related Keywords

United States ,Elizabeth Muhowski ,Mohammed Farooqui ,Johnc Byrd ,Ian Flinn ,Feng Chai ,Lindsey Granlund ,Arthurg James ,Sudharshan Eathiraj ,Sean Reiff ,Brian Schwartz ,Lily Ramsey ,Wayne Wang ,Lyndsey Szuszkiewicz ,Deborah Stephens ,Jennifer Woyach ,Razi Ghori ,Ohio State University Comprehensive Cancer Center ,Merck Co ,University Of Cincinnati College Medicine ,Huntsman Cancer Institute ,Leukemia Research Program ,Arqule Inc ,Richardj Solove Research Institute ,Sarah Cannon Research Institute ,Cancer Hospital ,Research Institute ,Seema Bhat ,Ronald Savage ,Cincinnati College ,Blood ,Blood Cancer ,Dancer ,Antibodies ,Fell ,Hronic ,Chronic Lymphocytic Leukemia ,Clinical Trial ,Drugs ,Nzyme ,Hodgkin Lymphoma ,Hospital ,Leukemia ,Lymphoma ,Non Hodgkin Lymphoma ,Research ,